Strongyloidiasis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
m (Changes made per Mahshid's request) |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Strongyloidiasis}} | {{Strongyloidiasis}} | ||
{{CMG}} ; {{AE}} {{ADG}} | {{CMG}}; {{AE}} {{ADG}} | ||
==Overview== | ==Overview== | ||
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or who are otherwise immunocompromised), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in patients with a [[immunosuppression|suppressed immune system]]. | If strongyloidiasis is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with [[HIV]] or who are otherwise immunocompromised), [[eosinophilic pneumonia]], [[malnutrition]], and [[malabsorption]]. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. [[Infections]] that are severe or widespread often have a poor outcome, especially in patients with a [[immunosuppression|suppressed immune system]]. | ||
| Line 10: | Line 10: | ||
==Complications== | ==Complications== | ||
Complications that can develop as a result of strongyloidiasis are:<ref name="pmid16304332">{{cite journal |vauthors=Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF |title=Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis |journal=Chest |volume=128 |issue=5 |pages=3681–4 |year=2005 |pmid=16304332 |pmc=1941746 |doi=10.1378/chest.128.5.3681 |url=}}</ref><ref name="GomezMaque2013">{{cite journal|last1=Gomez|first1=Juliana B.|last2=Maque|first2=Yvan|last3=Moquillaza|first3=Manuel A.|last4=Anicama|first4=William E.|title=E. coliMeningitis Presenting in a Patient with DisseminatedStrongyloides stercoralis|journal=Case Reports in Infectious Diseases|volume=2013|year=2013|pages=1–4|issn=2090-6625|doi=10.1155/2013/424362}}</ref> | Complications that can develop as a result of strongyloidiasis are:<ref name="pmid16304332">{{cite journal |vauthors=Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF |title=Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis |journal=Chest |volume=128 |issue=5 |pages=3681–4 |year=2005 |pmid=16304332 |pmc=1941746 |doi=10.1378/chest.128.5.3681 |url=}}</ref><ref name="GomezMaque2013">{{cite journal|last1=Gomez|first1=Juliana B.|last2=Maque|first2=Yvan|last3=Moquillaza|first3=Manuel A.|last4=Anicama|first4=William E.|title=E. coliMeningitis Presenting in a Patient with DisseminatedStrongyloides stercoralis|journal=Case Reports in Infectious Diseases|volume=2013|year=2013|pages=1–4|issn=2090-6625|doi=10.1155/2013/424362}}</ref> | ||
* [[Strongyloidiasis|Disseminated strongyloidiasis]](especially in patients with [[HIV]] and other [[immunocompromised]] conditions) | * [[Strongyloidiasis|Disseminated strongyloidiasis]](especially in patients with [[HIV]] and other [[immunocompromised]] conditions) | ||
* [[Sepsis causes|Polymicrobial sepsis]] including [[Meningitis causes|polymicrobial gram-negative meningitis]] | * [[Sepsis causes|Polymicrobial sepsis]] including [[Meningitis causes|polymicrobial gram-negative meningitis]] | ||
* [[Eosinophilic pneumonia]] | * [[Eosinophilic pneumonia]] | ||
| Line 18: | Line 18: | ||
==Prognosis== | ==Prognosis== | ||
With appropriate treatment | *With appropriate treatment people should make a full recovery. | ||
*Those who use oral or [[intravenous]] [[steroids]], for example, in patients with [[asthma]], [[chronic obstructive pulmonary disease]] ([[COPD]]) exacerbations, [[lupus]], [[gout]], or in persons using [[steroids]] for [[immunosuppression]] or symptomatic relief | *Sometimes, treatment needs to be repeated due to autoinfection. | ||
*Those with [[HTLV-1]] infection | *Infections that are severe or widespread often have a poor outcome, especially in patients with a [[immunosuppression|suppressed immune system]]. | ||
*Those with [[hematologic]] [[malignancies]] such as [[leukemia]] or [[lymphoma]] | *[[Strongyloidiasis]] could be severe and life-threatening in specific groups including: | ||
*[[Transplant|Transplant recipients]] | **Those who use oral or [[intravenous]] [[steroids]], for example, in patients with [[asthma]], [[chronic obstructive pulmonary disease]] ([[COPD]]) exacerbations, [[lupus]], [[gout]], or in persons using [[steroids]] for [[immunosuppression]] or symptomatic relief | ||
Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%. | **Those with [[HTLV-1]] infection | ||
**Those with [[hematologic]] [[malignancies]] such as [[leukemia]] or [[lymphoma]] | |||
**[[Transplant|Transplant recipients]] | |||
*Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%. | |||
==References== | ==References== | ||
| Line 31: | Line 34: | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:52, 18 September 2017
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis natural history, complications and prognosis |
|
FDA on Strongyloidiasis natural history, complications and prognosis |
|
CDC on Strongyloidiasis natural history, complications and prognosis |
|
Strongyloidiasis natural history, complications and prognosis in the news |
|
Blogs on Strongyloidiasis natural history, complications and prognosis |
|
Risk calculators and risk factors for Strongyloidiasis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
If strongyloidiasis is left untreated, the infection can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis (especially in patients with HIV or who are otherwise immunocompromised), eosinophilic pneumonia, malnutrition, and malabsorption. With appropriate treatment, people should make a full recovery. Treatment needs to be repeated often. Infections that are severe or widespread often have a poor outcome, especially in patients with a suppressed immune system.
Natural history
If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%.[1]
Complications
Complications that can develop as a result of strongyloidiasis are:[2][3]
- Disseminated strongyloidiasis(especially in patients with HIV and other immunocompromised conditions)
- Polymicrobial sepsis including polymicrobial gram-negative meningitis
- Eosinophilic pneumonia
- Malnutrition
- Malabsorption
- Intestinal perforation
Prognosis
- With appropriate treatment people should make a full recovery.
- Sometimes, treatment needs to be repeated due to autoinfection.
- Infections that are severe or widespread often have a poor outcome, especially in patients with a suppressed immune system.
- Strongyloidiasis could be severe and life-threatening in specific groups including:
- Those who use oral or intravenous steroids, for example, in patients with asthma, chronic obstructive pulmonary disease (COPD) exacerbations, lupus, gout, or in persons using steroids for immunosuppression or symptomatic relief
- Those with HTLV-1 infection
- Those with hematologic malignancies such as leukemia or lymphoma
- Transplant recipients
- Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%.
References
- ↑ Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.
- ↑ Newberry AM, Williams DN, Stauffer WM, Boulware DR, Hendel-Paterson BR, Walker PF (2005). "Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis". Chest. 128 (5): 3681–4. doi:10.1378/chest.128.5.3681. PMC 1941746. PMID 16304332.
- ↑ Gomez, Juliana B.; Maque, Yvan; Moquillaza, Manuel A.; Anicama, William E. (2013). "E. coliMeningitis Presenting in a Patient with DisseminatedStrongyloides stercoralis". Case Reports in Infectious Diseases. 2013: 1–4. doi:10.1155/2013/424362. ISSN 2090-6625.